Abbreviations
- ACT:
-
Adoptive cell therapy
- ALL:
-
Acute lymphoblastic leukemia
- AML:
-
Acute myeloid leukemia
- APC:
-
Antigen-presenting cell
- ATAP:
-
Advanced Therapy Access Program
- CAM-IR:
-
Cell adhesion-mediated immune resistance
- CLR:
-
C-type lectin receptor
- CR:
-
Complete response
- CRC:
-
Colorectal cancer
- CRPC:
-
Castration resistant prostate cancer
- CT:
-
Cancer testis
- Cy:
-
Cyclophosphamide
- DC:
-
Dendritic cell
- GAPVAC:
-
Glioma Actively Personalized Vaccine Consortium
- HGSC:
-
High grade serous carcinoma
- IFA:
-
Incomplete Freund’s adjuvant
- IVAC:
-
Individualized vaccines for cancer
- KNAW:
-
Royal Netherlands Academy of Arts and Sciences
- mDC:
-
Myeloid DC
- MDSC:
-
Myeloid-derived suppressor cell
- MM:
-
Multiple myeloma
- MoDC:
-
Monocyte-derived DC
- NGS:
-
Next-generation sequencing
- NLS:
-
Nuclear localization signal
- NSCLC:
-
Non-small-cell lung cancer
- OS:
-
Overall survival
- PDA:
-
Pancreatic ductal adenocarcinoma
- pDC:
-
Plasmacytoid DC
- PFS:
-
Progression-free survival
- PR:
-
Partial response
- RCC:
-
Renal cell cancer
- SLP:
-
Synthetic long peptide
- TIL:
-
Tumor infiltrating lymphocyte
- TRAMP:
-
Transgenic adenocarcinoma of mouse prostate
- TUMAP:
-
Tumor associated peptide
- T-VEC:
-
Talimogene laherparepvec
- VIN:
-
Vulvar intraepithelial neoplasia
- VSME:
-
Vaccine-site microenvironment
- WT-1:
-
Wilm’s tumor-1
Conflict of interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Sara M. Melief and Valeria V. Visconti have contributed equally to this work.
This meeting report is a summary of presentations from the Thirteenth International Conference on Progress in Vaccination against Cancer, PIVAC 13, published together with a series of Focussed Research Reviews based on lectures given at the conference.
Rights and permissions
About this article
Cite this article
Melief, S.M., Visconti, V.V., Doorduijn, E.M. et al. The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2–4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches. Cancer Immunol Immunother 63, 1105–1112 (2014). https://doi.org/10.1007/s00262-014-1532-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1532-0